Degrading the anaplastic lymphoma kinase protein to treat paediatric cancers
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Investigating a new type of drug that can inhibit the growth and survival of neuroblastoma and other childhood cancers
Professor Karim Malik and Dr Jodie Bojko are testing drugs that can prevent cancer cells from making growth-promoting proteins.
Creating advanced models to test new treatments for malignant rhabdoid tumours
Dr Daniel Williamson’s expert team will find the best malignant rhabdoid tumour models to test exciting new treatments.
Making CAR-T cells that can rest to improve their cancer-fighting ability
Professor John Anderson’s team at University College London Great Ormond Street Institute of Child Health aim to revolutionise CAR T-cell therapy for solid tumours.
Targeting metabolism in aggressive childhood blood cancers
Prof Jonathan Bond and Dr Marie-Claire Fitzgerald aim to find a treatment that can exploit a key weakness of acute myeloid leukaemia.
Unravelling the behaviour of individual lymphoma cells to find out why the cancer can relapse or resist treatment
Professor Suzanne Turner will investigate the behaviour of individual lymphoma cells in order to find out why treatments fail.
Finding the most beneficial dose of fludarabine to optimise CAR-T therapy
Dr Shelby Barnett and Dr Geoff Shenton will monitor crucial drug levels in patients' blood in order to improve CAR T therapy protocols.
Investigating the role of SET in childhood acute myeloid leukaemia to develop new treatments
Dr Maria Teresa Esposito hopes to learn more about a gene called SET in leukaemia and will test the best medicines to fight it.
Tracking individual osteosarcoma cells to understand how they dodge chemotherapy
Dr Lucia Cottone at University College London hopes to understand how osteosarcoma cells become resistant to chemotherapy, which has a big impact on patient survival.
Optimising drug treatment for childhood cancer patients
It is particularly difficult to treat some groups of childhood cancer patients, especially infants in their first weeks of life. This application is to fund this rapidly developing research programme for two years, involving the treatment of 150-200.
Fighting circular DNA to prevent relapse in acute lymphoblastic leukaemia
Looking at whether medicines that prevent circular DNA replication can help prevent relapse.
Understanding how a new drug can selectively fight childhood cancer cells
Testing a new type of targeted treatment that applies to multiple types of childhood cancers.
Looking for more?
Our partnership supports hundreds of Little Princess Trust-funded projects, from developing new treatments to understanding the causes of cancer.